Nektar Therapeutics (DE:ITH0)
NASDAQ:ITH0
ITH0 Stock Chart & Stats
€71.62
--
Market closed
€71.62
--
Day’s Range― - ―
52-Week Range€7.26 - €90.68
Previous CloseN/A
VolumeN/A
Average Volume (3M)28.00
Market Cap
€1.68B
Enterprise Value€1.28B
Total Cash (Recent Filing)€568.60M
Total Debt (Recent Filing)€143.43M
Price to Earnings (P/E)―
Beta2.66
Next Earnings
Aug 06, 2026EPS Estimate
-1.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.42
Shares Outstanding33,786,034
10 Day Avg. Volume21
30 Day Avg. Volume28
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)7.94
Price to Sales (P/S)12.91
P/FCF Ratio-3.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€132.90Price Target Upside85.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-7.79
Revenue Forecast (FY)€35.42M
Bulls Say, Bears Say
Bulls Say
Clinical Validation (AD Phase IIb)Durable, deepening Phase IIb AD results materially de-risk the lead program ahead of Phase III. Persistent efficacy and increasing EASI-100 rates support the planned registrational designs, underpin commercial positioning versus existing biologics and improve probability of successful late-stage readouts and label differentiation.
Strong Liquidity And RunwayA fortified balance sheet with over $1B pro forma cash and an explicit runway into Q3 2028 gives management flexibility to fund multiple Phase III programs, manufacturing scale-up and trial execution. This reduces near-term financing pressure and supports sustained development through key registrational milestones.
Differentiated MOA And SafetyTreg‑stimulating mechanism with a favorable safety profile versus JAK inhibitors is a durable competitive advantage for chronic inflammatory indications. Lower monitoring burden and improved tolerability can broaden prescriber adoption, ease payer acceptance, and support a differentiated commercial label if efficacy replicates in Phase III.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow (~-$204M TTM) means the business relies on financings or cash reserves to fund operations. As Phase III activity ramps, burn will likely increase, raising dilution risk, constraining strategic optionality, and making execution dependent on continued access to capital markets.
Large Operating And Net LossesDeep, persistent operating and net losses indicate profitability is a distant outcome. Negative margins depress returns on equity and necessitate ongoing external funding or partnerships, which can dilute shareholders, limit reinvestment capacity, and prolong the timeline to sustainable cash generation even if clinical success is achieved.
Regulatory & Execution Uncertainty For Phase IIIsGlobal Phase IIIs bring structural execution risk: large multi‑region site networks, CRO management and regulatory alignment (especially AA design questions) can delay timelines, increase costs or force protocol changes. These risks have lasting impact on time-to-market, development expense and ultimate commercial revenues.
Nektar Therapeutics News
ITH0 FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was €7.26 and its highest was €90.68 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is €1.68B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 60 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on May 07, 2026. The company reported -€1.554 earnings per share for the quarter, missing the consensus estimate of -€1.351 by -€0.203.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -1.74.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 33,786,034 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -€1.554 in its last earnings report, missing expectations of -€1.351. Following the earnings report the stock price went down -6.179%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in DE:ITH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€132.90 (85.56% Upside)
€132.90 (85.56% Upside)
Blogger Sentiment
Bullish
DE:ITH0 Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €36.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
466.29%
12-Months-Change
Fundamentals
Return on Equity
-87.00%
Trailing 12-Months
Asset Growth
197.87%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
ITH0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivered strong clinical progress and a clear, accelerated path to Phase III for REZPEG in atopic dermatitis and alopecia areata, supported by robust Phase IIb data (durable and deepening responses, EASI‑100 increases, SALT‑20 gains) and a fortified balance sheet (> $1B pro forma). Key positives include well‑defined Phase III designs, meaningful market opportunity, favorable safety signals versus JAK inhibitors, and additional pipeline and TrialNet collaboration in type 1 diabetes. Main concerns are typical biotech risks: ongoing net losses and increasing R&D spend as Phase III programs start, noncash interest expense, remaining regulatory/endpoint design questions (especially for AA and potential moderate AA expansion), and operational enrollment/execution risk for global trials. On balance, the positives (clinical validation, financing, program advancement) outweigh the near‑term financial and execution risks.View all DE:ITH0 earnings summariesITH0 Stock 12 Month Forecast
Average Price Target
€132.90
▲(85.56% Upside)
Technical Analysis
Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Options Prices
Currently, No data available
---